Abstract |
Analgesic studies of buprenorphine, a thebaine derivative and potent partial narcotic agonist, were carried out in patients with cancer who had postoperative or chronic pain. Intramuscular buprenorphine was compared with intramuscular morphine in a series of sequentially related, twin crossover assays and was found to be about 25 times as potent as morphine. Side effects were essentially morphine-like. In a second assay, the acceptability and analgesic activity of sublingual buprenorphine was studied in a 6-dose, balanced, incomplete block assay, a modification of the twin crossover design employed in the all-intramuscular trial. Sublingual buprenorphine was found to be about 15 times as potent as intramuscular morphine and was well accepted by our patients. The 4-dose twin crossover trial in which doses are adjusted sequentially is more flexible in that a wide range of doses may be studied, but it lacks the ability of the 6-dose design to provide estimates of the curvature of the dose-response slopes of the study drugs. When first-dose-only data were analyzed as parallel group assays, the main difference in results compared with the crossover studies was a decrease in efficiency and sensitivity.
|
Authors | S L Wallenstein, R F Kaiko, A G Rogers, R W Houde |
Journal | Pharmacotherapy
(Pharmacotherapy)
1986 Sep-Oct
Vol. 6
Issue 5
Pg. 228-35
ISSN: 0277-0008 [Print] United States |
PMID | 3540873
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
|
Topics |
- Administration, Oral
- Adult
- Aged
- Analysis of Variance
- Buprenorphine
(administration & dosage, adverse effects, therapeutic use)
- Chronic Disease
- Clinical Trials as Topic
- Double-Blind Method
- Female
- Humans
- Injections, Intramuscular
- Male
- Middle Aged
- Morphine
(adverse effects, therapeutic use)
- Mouth Floor
- Pain
(drug therapy)
- Pain, Postoperative
(drug therapy)
- Random Allocation
|